Literature DB >> 23775770

Evaluation of the oligosaccharide composition of commercial follicle stimulating hormone preparations.

Angela Lombardi1, Concetta Andreozzi, Vincenzo Pavone, Valeria Triglione, Luca Angiolini, Paolo Caccia.   

Abstract

Glycosylation is an important PTM in proteins, and it is of paramount importance for the manufacture and efficacy of therapeutic glycoproteins. The elucidation of the glycosylation patterns is greatly hampered by the structural heterogeneity, which involves the oligosaccharide moieties, and sometimes also the protein chain. Several strategies are used to map the glycosylation state of glycoproteins: they generally involve analysis of the glycopeptides obtained upon glycoprotein proteolytic digestion, and/or analysis of the glycans, enzymatic or chemically released from the glycoproteins. These approaches are efficient in determining the total glycan content, as well as the glycan structures; nevertheless, information regarding the whole protein is lost. Recent advances in MS allowed us to directly analyze human follicle stimulating hormone (hFSH). RP-HPLC/IT-TOF MS, coupled to bioinformatic algorithms, was used to determine the glycan content of intact hFSH preparations, either urinary-derived or recombinant. More traditional and complementary analytical methods (oligosaccharide profiling, IEF, and peptide mapping analyses) were employed to compare the obtained results. Our analysis shows a predominance of highly sialylated, highly branched glycans in a urinary hFSH preparation as compared to recombinant hFSH expressed in rodent cell lines. Noteworthy, high-resolution mass spectra may allow to evaluate the glycosylation profile during the manufacturing process of different preparations.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Glycosylation; Gonadotropin; Human follicle stimulating hormone; Liquid chromatography-mass spectrometry; N-glycan structure

Mesh:

Substances:

Year:  2013        PMID: 23775770     DOI: 10.1002/elps.201300045

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  6 in total

1.  Sequential (hFSH + recFSH) vs homogenous (hFSH or recFSH alone) stimulation: clinical and biochemical (cumulus cell gene expression) aspects.

Authors:  Timur Gurgan; Debbie Montjean; Aygul Demirol; Yves J R Menezo
Journal:  J Assist Reprod Genet       Date:  2014-03-18       Impact factor: 3.412

2.  Evaluation of in vivo bioactivities of recombinant hypo- (FSH21/18) and fully- (FSH24) glycosylated human FSH glycoforms in Fshb null mice.

Authors:  Huizhen Wang; Jacob May; Viktor Butnev; Bin Shuai; Jeffrey V May; George R Bousfield; T Rajendra Kumar
Journal:  Mol Cell Endocrinol       Date:  2016-08-22       Impact factor: 4.102

Review 3.  In Vivo and In Vitro Impact of Carbohydrate Variation on Human Follicle-Stimulating Hormone Function.

Authors:  George R Bousfield; Jeffrey V May; John S Davis; James A Dias; T Rajendra Kumar
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-09       Impact factor: 5.555

4.  Production of human pro-relaxin H2 in the yeast Pichia pastoris.

Authors:  D Cimini; K Della Corte; R Finamore; L Andreozzi; A Stellavato; A V A Pirozzi; F Ferrara; R Formisano; M De Rosa; M Chino; L Lista; A Lombardi; V Pavone; C Schiraldi
Journal:  BMC Biotechnol       Date:  2017-01-14       Impact factor: 2.563

5.  Structure of O-Antigen and Hybrid Biosynthetic Locus in Burkholderia cenocepacia Clonal Variants Recovered from a Cystic Fibrosis Patient.

Authors:  A A Hassan; Rita F Maldonado; Sandra C Dos Santos; Flaviana Di Lorenzo; Alba Silipo; Carla P Coutinho; Vaughn S Cooper; Antonio Molinaro; Miguel A Valvano; Isabel Sá-Correia
Journal:  Front Microbiol       Date:  2017-06-08       Impact factor: 5.640

Review 6.  Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization.

Authors:  Loredana Bergandi; Stefano Canosa; Andrea Roberto Carosso; Carlotta Paschero; Gianluca Gennarelli; Francesca Silvagno; Chiara Benedetto; Alberto Revelli
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.